- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04152655
A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD)
July 14, 2021 updated by: Second Affiliated Hospital, School of Medicine, Zhejiang University
A Study of Efficacy and Safety of Idebenone vs. Placebo in Prodromal Parkinson Disease (SEASEiPPD)
To investigate whether 24 months of idebenone may reduce the progression from Prodromal Parkinson disease (PPD) to Parkinson disease (PD).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Number of people suffered from Parkinson disease (PD) is increasing every year.
Contemporary medication has little neuroprotective effect, which may due to delayed treatment as over 50% neurons have lost when clinical diagnosed PD emerges.
The concept of Prodromal Parkinson disease (PPD) is emphasized as it has become evident that there are several risk and clinical markers may occur years before the cardinal motor symptoms which allow clinical diagnosis.
Rapid eye movement (REM) sleep behavior disorder and olfactory dysfunction are the most common PPD, and more than one third of patients may progress to PD and other neurodegenerative diseases.
Mitochondrial injury is one of the pathogenesis of PD.
Thus we design this trial to investigate whether idebenone, potent coenzyme Q10 analogue, could protect PPD develops into PD.
Study Type
Interventional
Enrollment (Anticipated)
180
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Baorong Zhang, MD
- Phone Number: +86 13958167260
- Email: brzhang@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Recruiting
- Second Affiliated Hospital of Zhejiang University School of Medicine
-
Contact:
- Baorong Zhang, MD
- Phone Number: +86 13958167260
- Email: brzhang@zju.edu.cn
-
Principal Investigator:
- Baorong Zhang, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects are voluntary to participate and have signed informed consent
- Diagnosed as Rapid Eye movement (REM) Sleep Behavior Disorder by polysomnography
Exclusion Criteria:
- Subjects are pregnant, breastfeeding, or want to get pregnant or breastfeeding in 2 years
- Subjects have history of allergy to idebenone
- Difficulty to communicate
- Suffering from neurodegenerative diseases
- Having obvious brain imaging abnormalities (eg. severe brain atrophy, malformation, softening lesions, cerebrovascular disease, intracranial occupancy, giant large benign lesions, etc.)
- Having severe mental illness (eg. schizophrenia, manic depression, and severe depression)
- Long-term use of clonidine, dopamine antagonists, and serotonin reuptake inhibitors
- Suffering from other severe medical conditions
- Having difficulty in moving and are unable to come to the hospital
- Having claustrophobia
- Having contraindications to MRI tests
- Having history of olfactory disorders greater than 10 years
- Having history of color vision disorders greater than 10 years
- Life expectancy less than 2 years
- Having other situations which researchers consider is inappropriate to participate in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Group 1: idebenone
Oral 30 mg fixed dose three times a day x 24-months (90 mg total / day) with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months
|
30mg tablets three times a day
Other Names:
|
PLACEBO_COMPARATOR: Group 2: placebo
Oral placebo three times a day x 24-months with assessments @ baseline, 3 month, 6 month, 12 month, 15 month, 18 month, 21 month and 24 months
|
placebo tablets three times a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical diagnosis of parkinson disease
Time Frame: 24 months
|
based on Movement Disorder Society (MDS) Research Criteria for Prodromal Parkinson's Disease in 2015
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dopamine transporter positron emission tomography (DAT-PET) change
Time Frame: 12 month and 24 month
|
diminishment of striatal DAT-PET
|
12 month and 24 month
|
Quantitative motor testing change
Time Frame: 24 months
|
Unified Parkinson Disease Rating Scale, Part III
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Chair: Baorong Zhang, MD, Second Affiliated Hospital of Zhejiang University School of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 1, 2020
Primary Completion (ANTICIPATED)
January 1, 2022
Study Completion (ANTICIPATED)
January 1, 2023
Study Registration Dates
First Submitted
October 7, 2019
First Submitted That Met QC Criteria
November 3, 2019
First Posted (ACTUAL)
November 5, 2019
Study Record Updates
Last Update Posted (ACTUAL)
July 16, 2021
Last Update Submitted That Met QC Criteria
July 14, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Sleep Wake Disorders
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parasomnias
- REM Sleep Parasomnias
- Parkinson Disease
- Mental Disorders
- REM Sleep Behavior Disorder
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Coenzyme Q10
- Idebenone
Other Study ID Numbers
- 2019-278
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Idebenone
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Santhera PharmaceuticalsCompletedFreidreich's AtaxiaGermany, Netherlands, France, Austria, Belgium
-
Beijing Tiantan HospitalRecruiting
-
Second Affiliated Hospital of Soochow UniversityQilu Pharmaceutical Co., Ltd.UnknownOxidative Stress is an Important Cause of Parkinson's Disease
-
Santhera PharmaceuticalsCompletedFriedreich's AtaxiaNetherlands, Austria, United Kingdom, Belgium, France, Germany
-
Xiangya Hospital of Central South UniversityRecruitingPost Stroke EpilepsyChina
-
Santhera PharmaceuticalsCompletedDuchenne Muscular Dystrophy (DMD)Belgium
-
Santhera PharmaceuticalsTerminatedDuchenne Muscular Dystrophy (DMD)United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
-
Santhera PharmaceuticalsNo longer availableLeber's Hereditary Optic Neuropathy
-
Santhera PharmaceuticalsTerminatedDuchenne Muscular DystrophyUnited States, Belgium, United Kingdom, Austria, France, Germany, Italy, Spain, Switzerland